The cost of clean-up: Oil spill responders in the Gulf of

New Post Public Reply Private Reply Replies (1) Message Board
wowhappens28
218
The cost of clean-up: Oil spill responders in the Gulf of Mexico exposed to chemical dispersants now have health issues

I can believe some of the seafood we eat from the Guld is not that great either.

https://www.naturalnews.com/2018-03-27-oil-sp...ssues.html

Cleaning up oil spills is always a dirty and dangerous job, but a new study revealed its hidden health cost. According to Environmental Health Perspectives, two of the chemical dispersants used to clear up the Deepwater Horizon disaster of 2010 have been linked to numerous health problems reported by oil spill response crews after the event.

The National Institute of Environmental Health Sciences (NIH) study looked at the link between potential exposure to Corexit dispersants used during the clean-up and health complaints by oil spill workers.

This is the first study to distinguish the potential health effects of dispersants from those of crude oil exposure. Previous studies lumped them all together.

Furthermore, existing research on chemical dispersants focused on their effect on marine species instead of humans.

The Deepwater Horizon oil spill is the biggest disaster of its kind in U.S. history. Cleaning it up required around 1.8 million gallons of Corexit dispersants, as well as other oil spill mitigation techniques.

Oil dispersants reduce the surface tension that prevents oil and water from mixing together. Their surfactant action allows large oil slicks to be broken down into much smaller groups that can be scattered by wind and wave action.

These chemicals first saw use in the 1960s. But even the Exxon Valdez oil spill of 1989 did not require the massive amount of dispersants employed during the Deepwater Horizon oil spill.

“It is important to understand the potential toxicity of any chemical released in such large volumes to which workers or the public may be exposed,” explained environmental toxicologist Bernard Goldstein, who studied the potential ill effects of chemical dispersants on human health.

Workers exposed to chemical dispersants reported more symptoms
The NIH study conducted a telephone survey of at least 27,659 workers from 2011 to 2013. The participants belonged to an active study of long-term health outcomes for Deepwater Horizon clean-up crews.

Participants were quizzed about health symptoms they experienced during and after the clean-up. If they worked directly with Corexit products, worked on a ship that deployed the chemicals, or worked with related equipment for more than half the time, they were classified as “exposed to dispersants.”

Researchers also factored in time, work location, and estimated co-exposures to crude oil and other chemical decontaminants. (Related: Severe “ecological injury” has already been caused by the Sanchi oil spill, which is now threatening reefs, protected marine areas and the fishing industry.)

According to the researchers, workers with potential exposures to chemical dispersants showed higher likelihood of reporting negative symptoms during the clean-up. They found a weaker link between potential chemical exposure and symptoms that took place months after the event.

“It was reassuring that many of those who reported symptoms during the spill no longer had them one to three years later,” remarked Dale Sandler, the leader of the NIH research team.

“We were surprised to see that some of the workers who were exposed to oil dispersants and did not report having symptoms while they were working on the cleanup reported having them when they enrolled in the study,” she added.

According to Sandler, this result could be attributed to people being more able to report accurately on what they are currently feeling compared to recalling what they experienced in the past. She also theorized that part of the link between dispersant exposure and current symptoms can be traced to people over-reporting their symptoms.

Furthermore, she said that the effect of the symptoms on long-term health are still unknown.

“We do not yet know whether exposures during the oil spill will be associated with clinical disease down the road,” she noted.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading